12:00 AM
 | 
May 12, 2008
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 5/9 cls
Array BioPharma (NASDAQ:ARRY) Piper Jaffray Edward Tenthoff Price target Buy -8% $5.75
Rodman Michael King Price target Market outperform
Tenthoff lowered his target to $13 from $17 after he reduced his projected enterprise value to $595M from $795M. He blames the market for compressing the value of early stage assets. Tenthoff also lowered his FY08 revenue estimate to $28.7M from $29M.
King lowered his target to $15 from $18 to reflect additional warrants issued by the company in its $80M financing from Deerfield Management (see B19). Next quarter he expects Phase II data on ARRY-797 in dental pain and the start of a Phase II trial of the P38 mitogen-activated protein (MAP) kinase inhibitor to treat ankylosing spondylitis.
Barrier (NASDAQ:BTRX) Susquehanna Angela Larson Price target Net positive 3% $2.37
Larson lowered her target to $4 from $4.75 after the company reported lower than expected 1Q sales of Vusion for diaper dermatitis and Xolegel for seborrheic dermatitis. She believes a positive for the stock is a plan to suspend development of the "higher risk or expense programs," including Rambazole for psoriasis and Pramiconazole for fungal infections, until...

Read the full 1292 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >